Pacmilimab is under clinical development by CytomX Therapeutics and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Pacmilimab’s likelihood of approval (LoA) and phase transition for Adenocarcinoma took place on 11 Feb 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

In addition, the same event on 11 Feb 2022 increased Pacmilimab’s LoA and PTSR for Anal Cancer, increased LoA and PTSR for Bladder Cancer, increased LoA and PTSR for Cervical Cancer, increased LoA and PTSR for Esophageal Cancer, increased LoA and PTSR for Gastric Cancer, increased LoA and PTSR for Gastroesophageal (GE) Junction Carcinomas, increased PTSR for Testicular Cancer, increased LoA and PTSR for Thymic Carcinoma, decreased LoA and PTSR for Triple-Negative Breast Cancer (TNBC), increased LoA and PTSR for Uterine Cancer, increased PTSR for Pancreatic Cancer, increased PTSR for Rectal Cancer, increased LoA and PTSR for Salivary Gland Cancer, increased LoA and PTSR for Skin Cancer, increased PTSR for Small Intestine Cancer, increased LoA and PTSR for Squamous Cell Carcinoma, increased PTSR for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, increased LoA and PTSR for Lymphoma, increased LoA and PTSR for Merkel Cell Carcinoma, decreased LoA and PTSR for Metastatic Breast Cancer, increased LoA and PTSR for Mycosis Fungoides, and decreased LoA and PTSR for Non-Small Cell Lung Cancer.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Pacmilimab Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Pacmilimab overview

CX-072 is under development for the treatment of solid tumors including lymphomas, non-small cell lung cancer, bladder cancer, colon adenocarcinoma, triple negative breast cancer, gastric, gastroesophageal junction (GEJ) tumors, esophageal cancer, castration-resistant prostate cancer, esophageal carcinoma, cervix carcinoma, pancreatic carcinoma, ovarian Cancer, mycosis fungoides uterine carcinoma, rectal carcinoma, uterine sarcoma, cervical cancer and testicular cancer, undifferentiated pleiomorphic sarcoma, thymic epithelial cancer, anal squamous cell cancer (SCC), cutaneous squamous cell cancer (cSCC), Merkel cell tumor, small bowel carcinoma and cancers with high tumor mutational burden. It is administered through intravenous route. The monoclonal antibody acts by targeting programmed cell death ligand-1 (PDL-1). The drug candidate is developed based on Probody platform. Probodies are fully recombinant masked antibodies that remain inert in healthy tissue but are activated specifically in the disease microenvironment. It was also under development for metastatic melanoma, metastatic HR-positive/HER2-negative breast cancer.

CytomX Therapeutics overview

CytomX Therapeutics (Cytomx) is a clinical-stage biopharmaceutical company. it develops novel therapeutic antibodies and Probody therapeutics for the treatment of cancer. The company’s leading product candidates include CX-072, CX-2009, BMS-986249, CX-2029, CX-188, pro body drug conjugate, and T-cell bispecific. Its products CX-072, is a PD-L1 targeting Probody therapeutic for the treatment of cancer; CX-2009, currently under is a CD166-directed PDC for the treatment of cancer; BMS-986249, under Phase is a CTLA-4-directed Probody therapeutic intended for the treatment of solid cancers; CX-2029, under is a PDC directed against CD71 intended for the treatment of B-cell lymphoma; CX-188, is a PD-1-targeting Probody therapeutic. The company also carries out various phases of clinical trails. Cytomx is headquartered in South San Francisco, California, the US.

Quick View Pacmilimab LOA Data

Report Segments
  • Innovator
Drug Name
  • Pacmilimab
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.